Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
| Condition | Intervention | Phase |
|---|---|---|
|
Atherosclerosis Cardiovascular Diseases Hypertension, Renovascular Renal Artery Obstruction |
Drug: Atacand/HCT, Caduet Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) |
- Cardiovascular or renal death [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
- Myocardial infarction [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
- Hospitalization for congestive heart failure [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
- Stroke [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
- 30% reduction of eGFR from Baseline, persisting for greater than or equal to 60 days [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
- Need for renal replacement therapy [ Time Frame: Measured at every 3 months for the first year and annually thereafter ] [ Designated as safety issue: Yes ]
| Enrollment: | 947 |
| Study Start Date: | April 2004 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Optimal Medical Therapy
Optimal anti-hypertensive therapy
|
Drug: Atacand/HCT, Caduet
Atacand/HCT and caduet or optimal medical therapy for hypertension
|
|
Experimental: Stenting
Stent procedure plus optimal anti-hypertensive therapy
|
Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
Either
- Documented history of hypertension on two or more anti-hypertensive medications OR
- Renal dysfunction, defined as Stage 3 or greater chronic kidney disease (CKD) based on the new National Kidney Foundation (NKF) classifications (estimated glomerular filtration rate [GFR] less than 60 mL per minute per 1.73 m^2, calculated by the modified Modification of Diet in Renal Disease [MDRD] formula)
One or more severe renal artery stenoses by any of the following pathways:
a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram OR b. Duplex: systolic velocity of greater than 300 cm/sec OR c. Core Lab approved Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria) demonstrating stenosis greater than 80% OR stenosis greater than 70% with spin dephasing on 3D phase contrast MRA OR stenosis greater than 70% and two of the following: i. Ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Ischemic kidney enhances less on arterial phase iii. Ischemic kidney has delayed Gd excretion iv. Ischemic kidney hyper-concentrates the urine v. 2-D phase contrast flow waveform shows delayed systolic peak vi. Post-stenotic dilatation d. Clinical index of suspicion combined with a Core Lab approved Computed Tomography Angiography (CTA) demonstrating Stenosis is greater than 80% by visual assessment on high quality CTA Stenosis is greater than 70% on CTA by visual assessment and there are two of the following i. The length of the ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Reduced cortical thickness of ischemic kidney iii. Less cortical enhancement of ischemic kidney on arterial phase iv. Post-stenotic dilatation
EXCLUSION CRITERIA:
- Unable to provide informed consent
- Unable or willing to comply with study protocol or procedures
- Must be greater than 18 years of age
- Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization
- Pregnancy or unknown pregnancy status in female of childbearing potential
- Participation in any drug or device trial during the study period, unless approved by the Steering Committee
- Prior enrollment in the CORAL study
- History of stroke within 6 months, if associated with a residual neurologic deficit*
- Any major surgery, major trauma, revascularization procedure, unstable angina, or myocardial infarction 30 days prior to study entry*
- Any planned major surgery or revascularization procedure, outside of the randomly allocated renal stenting indicated by the protocol, after randomization*
- Hospitalization for heart failure within 30 days*
- Comorbid condition causing life expectancy of less than or equal to 3 years*
- Allergic reaction to intravascular contrast, not amenable to pre-treatment
- Allergy to stainless steel
- Allergy to all of the following: aspirin, clopidogrel, ticlopidine
- Known untreated aneurysm of the abdominal aorta greater than 5.0 cm.*
- Previous kidney transplant
- a. Stenosis of greater than 50% of a previously treated revascularized renal artery OR b. Treatment of any renal artery stenosis within the past 9 months (roll-in patients can have prior treatment on the contralateral side)
- Kidney size less than 7 cm. supplied by target vessel
- Hydronephrosis, nephritis or other known cause of renal insufficiency, not due to large vessel renal artery stenosis
- Visualized stenosis of only an accessory renal artery supplying greater than 1/2 of the ipsilateral renal parenchyma, without stenosis in a dominant renal artery
- Local lab serum Cr greater than 4.0 mg/dl on the day of randomization*
Presence of a renal artery stenosis not amenable for treatment with a stent, known to be present prior to randomization
- The index lesion cannot be treated with a single stent (i.e. greater than 18 mm. in length)
- The placement of a stent will necessitate covering a renal artery branch renal artery with a stent
- The stenosis is in an artery less than 3.5 mm. in diameter
- The stenosis involves a segmental renal artery branch
- Abrupt vessel closure or dissection after diagnostic angiography [NOTE: Patients with abrupt vessel closure or dissection as a result of diagnostic angiography will not be randomized but will undergo stent revascularization, receive optimal medical therapy and will be followed for the full study period] *Roll-in patients do not need to meet these inclusion/exclusion criteria
Contacts and Locations| United States, Ohio | |
| University of Toledo | |
| Toledo, Ohio, United States, 43614 | |
| Principal Investigator: | David Cohen, MD | Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO |
| Principal Investigator: | Christopher J. Cooper, MD | University of Toledo |
| Principal Investigator: | Donald Cutlip, MD | Beth Israel Deaconess Medcial Center |
| Principal Investigator: | Alan Matsumoto, MD | University of Virginia School of Medicine |
| Principal Investigator: | Michael Steffes, MD | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Timothy P Murphy, MD | Rhode Island Hospital |
| Study Chair: | Scott D Solomon, MD | Brigham and Women's Hospital |
| Study Chair: | Lance D Dworkin, MD | Rhode Island Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | Ingrid Abrahamsen, MS, Project Coordinator, Harvard University |
| ClinicalTrials.gov Identifier: | NCT00081731 History of Changes |
| Other Study ID Numbers: | 161, U01 HL71556 |
| Study First Received: | April 19, 2004 |
| Last Updated: | January 15, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Atherosclerosis Cardiovascular Diseases Hypertension Hypertension, Renovascular Renal Artery Obstruction Arterial Occlusive Diseases Arteriosclerosis Vascular Diseases Hypertension, Renal Kidney Diseases Urologic Diseases Candesartan cilexetil Amlodipine, atorvastatin drug combination Angiotensin II Type 1 Receptor Blockers |
Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Enzyme Inhibitors Lipid Regulating Agents Calcium Channel Blockers Membrane Transport Modulators |
ClinicalTrials.gov processed this record on May 19, 2013